Robert B Chao, MD doctorRBC
1 year 10 months ago
In vitro study shows Upadacitinib inhibits enthesis T cell derived TNFa and IL-17A, disrupting the prominent IL-23/IL-17/TNFa axis driving SpA.
@RheumNow #EULAR2022 ABST#POS0331 https://t.co/pNL3Zlgmt7
Dr. John Cush RheumNow
1 year 10 months ago
RheumNow’s coverage of the #EULAR2022 annual meeting is sponsored in part by Bristol-Myers Squibb. All content is chosen by RheumNow & its Faculty.
David Liew drdavidliew
1 year 10 months ago
Rituximab/belimumab patients & COVID vaccination response:
may have had average antibody response
but there’s still the cellular response to consider too! Not as bad.
Still caution++, but when ritux really needed we’ll find a way despite COVID
from roundup #EULAR2022 @RheumNow https://t.co/zFr6QI9TOG
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 10 months ago
#OP0236 #EULAR2022 Prof Schulze-Koops highlighted a mechanistic study that baricitinib therapy ex vivo suppressed autophagy, increased apoptosis, and reduced expression of adhesion molecules in #sjogren salivary glands. Next step should be randomised controlled trial @RheumNow https://t.co/dirmHY9cYJ
David Liew drdavidliew
1 year 10 months ago
Sex differences in axSpA: we’re continuing to better understand the differences in imaging findings.
Existing MRI scoring may underserve axSpA in women.
Added to therapy differences, a lot to readdress for our female axSpA patients.
from roundup #EULAR2022 @RheumNow https://t.co/8wCKx9AFcM
Aurelie Najm AurelieRheumo
1 year 10 months ago
#highlight n•1 💫
The presence of specific peripheral blood T cell sub-populations associated w/ disease flares
in RA pts in remission after cs or bioDMARDs tapering or cessation
identified in 2 different abstracts
OP0011 and OP0074
@RheumNow #EULAR2022 https://t.co/SO2AgtkyTP
Robert B Chao, MD doctorRBC
1 year 10 months ago
Gut microbiome of AS patients different from healthy controls. Different bacteria communities may be associated with disease activity.
So much more to digest....
@RheumNow #EULAR2022 ABST#POS0330 https://t.co/EAvHngd6SD
Eric Dein ericdeinmd
1 year 10 months ago
#EULAR2022 POS0282
Febuxostat vs allopurinol: CV risk population study
⭐️16% reduction in all-cause mortality among febuxostat users, mostly non-CV death reduction
⭐️CV safety non-inferior to allopurinol
@Rheumnow https://t.co/1oDSioQWPT
Richard Conway RichardPAConway
1 year 10 months ago
Stimakovits et al. Influence of placebo vs active comparator in RA clinical trials. ACR response rates systematically higher in studies with active comparators. ACR20 OR 1.64 (1.44-1.86), ACR50 OR 1.46 (1.28-1.71), ACR70 OR 1.61 (1.28-2.02) @RheumNow #EULAR2022 POS0563 https://t.co/x7PQH11oue
David Liew drdavidliew
1 year 10 months ago
We’re in the #EULAR2022 highlights: basic/translational first. Wait, don’t go…
because Temra cells are cool. Up in RA pts who are TNFi-IR, & may actually be more than a bystander.
Understanding TNFi resistance is path to:
predicting it
knowing best what to do with it
@RheumNow https://t.co/22Y6iinSbH
Robert B Chao, MD doctorRBC
1 year 10 months ago
Psoriasis and Psoriatic arthritis patients have different circulating microRNA signatures compared to healthy controls.
(miRNAs: non-coding RNAs controlling gene expression)
PsO/PsA miRNAs involved in bone metabolism
@RheumNow #EULAR2022 ABST#POS0314
Eric Dein ericdeinmd
1 year 10 months ago
#EULAR2022 POS0283: Do Rheums have Gout Stigma?
⭐️Stereotypes about pt related factors
⭐️Rheumatologists feel diet, exercise, wt loss more important in gout than RA, pharmacologic therapies less important than RA
@Rheumnow
Richard Conway RichardPAConway
1 year 10 months ago
Li et al. Orelabrutinib in SLE. 60 patient phase 2 RCT. Week 12 SRI(4) 50.0%/61.5%/64.3% in orelabrutinib groups vs 35.7% PBO. @RheumNow #EULAR2022 LB0005 https://t.co/u0UUWKal7n https://t.co/aYFf7Lpx1L
David Liew drdavidliew
1 year 10 months ago
PMR on the podium @profbdasgupta, with a positive phase 3!
Sarilumab in relapsing PMR (SAPHYR):
sari q2w+14w taper vs placebo+52w taper
underrecruited 118/280 (COVID) but still hit primary, almost all secondary
Better outcome + steroid-sparing: big
LB0006 #EULAR2022 @RheumNow https://t.co/nd3TSibYa0